A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Conditions:   B-cell Lymphoma;   Non-Hodgkin Lymphoma;   B-cell Malignancy;   Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL);   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Large B-cell Lymphoma Intervention:   Biological: CTX112 Sponsor:   CRISPR Therapeutics AG Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials